Unmet need in diabetic nephropathy: failed drugs or trials?

被引：40

作者：

de Zeeuw, Dick ^{[1
]}

Heerspink, Hiddo J. L. ^{[1
]}

机构：

[1] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, NL-9700 RB Groningen, Netherlands

来源：

LANCET DIABETES & ENDOCRINOLOGY | 2016年 / 4卷 / 08期

关键词：

CHRONIC KIDNEY-DISEASE; BARDOXOLONE METHYL; TYPE-2; RENOPROTECTION; OUTCOMES; RENAAL; RISK;

D O I：

10.1016/S2213-8587(16)30045-6

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：638 / +

页数：4

共 15 条

[1] Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].

Brenner, BM ;

Cooper, ME ;

de Zeeuw, D ;

Keane, WF ;

Mitch, WE ;

Parving, HH ;

Remuzzi, G ;

Snapinn, SM ;

Zhang, ZX ;

Shahinfar, S .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869

[2] Risk Factors for Heart Failure in Patients With Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated With Bardoxolone Methyl [J].

Chin, Melanie P. ;

Wrolstad, Danielle ;

Bakris, George L. ;

Chertow, Glenn M. ;

de Zeeuw, Dick ;

Goldsberry, Angie ;

Linde, Peter G. ;

McCullough, Peter A. ;

McMurray, John J. ;

Wittes, Janet ;

Meyer, Colin J. .

JOURNAL OF CARDIAC FAILURE, 2014, 20 (12) :953-958

[3] Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL [J].

de Zeeuw, D ;

Remuzzi, G ;

Parving, HH ;

Keane, WF ;

Zhang, ZX ;

Shahinfar, S ;

Snapinn, S ;

Cooper, MF ;

Mitch, WE ;

Brenner, BM .

KIDNEY INTERNATIONAL, 2004, 65 (06) :2309-2320

[4]

de Zeeuw D, 2014, J AM SOC NEPHROL, V25, p578A

[5] Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease [J].

de Zeeuw, Dick ;

Akizawa, Tadao ;

Audhya, Paul ;

Bakris, George L. ;

Chin, Melanie ;

Christ-Schmidt, Heidi ;

Goldsberry, Angie ;

Houser, Mark ;

Krauth, Melissa ;

Heerspink, Hiddo J. Lambers ;

McMurray, John J. ;

Meyer, Colin J. ;

Parving, Hans-Henrik ;

Remuzzi, Giuseppe ;

Toto, Robert D. ;

Vaziri, Nosratola D. ;

Wanner, Christoph ;

Wittes, Janet ;

Wrolstad, Danielle ;

Chertow, Glenn M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (26) :2492-2503

[6] Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy [J].

Fried, Linda F. ;

Emanuele, Nicholas ;

Zhang, Jane H. ;

Brophy, Mary ;

Conner, Todd A. ;

Duckworth, William ;

Leehey, David J. ;

McCullough, Peter A. ;

O'Connor, Theresa ;

Palevsky, Paul M. ;

Reilly, Robert F. ;

Seliger, Stephen L. ;

Warren, Stuart R. ;

Watnick, Suzanne ;

Peduzzi, Peter ;

Guarino, Peter .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (20) :1892-1903

[7] Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial [J].

Heerspink, H. J. L. ;

Ninomiya, T. ;

Persson, F. ;

Brenner, B. M. ;

Brunel, P. ;

Chaturvedi, N. ;

Desai, A. S. ;

Haffner, S. M. ;

McMurray, J. J. V. ;

Solomon, S. D. ;

Pfeffer, M. A. ;

Parving, H. -H. ;

de Zeeuw, D. .

DIABETES OBESITY & METABOLISM, 2016, 18 (02) :169-177

[8]

Heerspink Hiddo J Lambers, 2011, Rev Diabet Stud, V8, P392, DOI 10.1900/RDS.2011.8.392

[9] The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study [J].

Keane, WF ;

Brenner, BM ;

de Zeeuw, D ;

Grunfeld, JP ;

McGill, J ;

Mitch, WE ;

Ribeiro, AB ;

Shahinfar, S ;

Simpson, RL ;

Snapinn, SM ;

Toto, R .

KIDNEY INTERNATIONAL, 2003, 63 (04) :1499-1507

[10] Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes [J].

Lewis, EJ ;

Hunsicker, LG ;

Clarke, WR ;

Berl, T ;

Pohl, MA ;

Lewis, JB ;

Ritz, E ;

Atkins, RC ;

Rohde, R ;

Raz, I .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :851-860

← 1 2 →